absurdly cheap from thestreet.com

http://www.thestreet.com/story/11756249/1/sunshine-heart-a-promising-treatment-for-heart-failure-patients.html


There is massive upside in Sunshine Heart if the C-Pulse pivotal trials are successful in showing clear advantage over current therapy for Class III and ambulatory Class IV heart failure patients. Even factoring in a highly dilutive stock offering in a year or so, the Sunshine Heart's shares are still absurdly cheap. Despite the lack of near-term catalysts, I'm comfortable buying the stock today and wait the time necessary for the stock to turn into a big winner.

Rosenblum is long Sunshine Heart.


( I dont know about the highly dilutive comment , considering the other options available discussed in last Sunshine presentation , even so market cap could be double or triple by the time there is a raising so it wont be highly dilutive then either.)